Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 10, 2020 / 05:30PM GMT
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Okay. Welcome, everybody. I am Marty Auster, I'm the lead mid-cap biotech analyst here at Credit Suisse. Thank you for joining us today. We're going to be hosting now BioMarin for a fireside chat at the 29th Annual Credit Suisse Biotech Healthcare Conference. I am joined today by CEO, J.J. Bienaimé; and CFO, Brian Mueller.

And maybe just to kick off before we get into some of the details, J.J., if you could kind of just give us a little bit of the strategic overview of BioMarin and talk to us a little bit about your vision for the next kind of few years and kind of framework of BioMarin out in your mind. And also, again, I'd like to thank you guys for joining us today. J.J.?

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Thank you, Martin. So I'll be brief because we recently had our third quarter conference call. And the company obviously had a lot of news this year.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot